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Abstract
Background: The prevalence of Pediatric Functional Constipation (FC) has been reported between 0.7% to 29.6%.
This study was conducted to compare the laxative effect of cassia fistula emulsion (CFE) with mineral oil (MO) on
FC. Cassia fistula is named in Traditional Iranian Medicine (TIM) as “Folus”.
Materials and methods: A randomized clinical trial was carried on 81 children (age range: 4–13 years) with FC,
according to Rome III criteria in Amirkola Children’s Hospital, Babol, Iran. They received CFE or MO randomly for
three weeks. CFE was produced according to the order of TIM references. Children were counted as improved
when they exited from Rome III criteria of FC. Frequency of defecation, fecal incontinence, retentive posturing,
severity of pain, consistency of stool and anal leakage of oily material were compared between the two groups
and with baselines. An intent-to-treat analysis was used. Safety of drugs was assessed with the evaluation of clinical
adverse effects.
Results: 41 children were assigned randomly to receive CFE and 40 children received MO. After three weeks of
medication, 84% of children in CFE group and 50% in MO group (p = 0.002) exited from the criteria of FC, so called
improved. All measurable criteria improved in both groups. The frequency of defecation in CFE group improved
from 1.7 per week (before the study) to 10.6 per week (at the third week) while this parameter differed in MO
group from 2 to 6.1 (p < 0.001). The severity of pain during defecation and consistency of stool improved
significantly better in CFE group than MO group (p < 0.05), but there were not any significant differences between
the two groups in fecal incontinence and retentive posturing. Anal leakage of oily material occurred as an
important complication in MO group while the children in CFE group did not complaint it. Drug’s compliances
were not significantly different in the two groups. CFE and MO did not cause clinically significant side effects.
Conclusions: CFE was most effective than MO in the 3-week treatment of children with FC.
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Randomized Clinical Trial (RCT)
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Functional constipation represent the common pro-
blems in childhood [1]. Constipation entails more than
3% of visits to pediatricians and 10% to 25% of visits
to pediatric gastroenterologists [2,3]. The etiology is
usually functional, and only a few cases are diagnosed
as suffering an organic pathology [4]. Laxatives drugs
mostly include bulking, osmotic, lubricating and stimu-
lant agents [5].
Today, many people seek help from natural based drugs
[6] and complementary and alternative medicine [7]. In a
literature review of Traditional Iranian Medicine (TIM),
we found 134 plants can be used for treatment of consti-
pation [8]. One of the low potent and probably safe and
effective plants for the treatment of constipation is cassia
fistula (called in TIM, “Folus” or “Khiar shanbar”). The
different compounds of cassia fistula are found in TIM
book references [9,10].
Cassia fistula L. (Leguminosae) is cultivated in the tro-
pics like the West Indies, Ceylon, China, Egypt, Amazon,
Sri Lanka and many other countries, and is widely used
in traditional medicine for children and pregnant women
[11] as mild laxative and also as purgative [12]. Its anti-
oxidant [13-16] and hepatoprotective effects [17-20]
have been proven. Other therapeutic uses such as immu-
nomodulator, wound healing, antifertility and antiparasi-
tic effects in herbal medicine [11,21-26] and Ayurvedic
medicine [13] have been mentioned in literatures. Any
serious complication has not been reported in these
studies.
Although, cassia fistula has cathartic and laxative
effect because of the anthraquinone derivatives isolated
from the pulp of the its fruits [11,12,27], we did not
find any clinical trial research about it. Therefore, we
designed a prospective, randomized clinical trial to
compare the efficacy, safety, and patient compliance of
cassia fistula emulsion (CFE) by a formula of TIM [10]
vs mineral oil (MO) that is the most commonly used
lubricant laxative [5,28] in the treatment of pediatric
functional constipation (FC).
Methods and materials
Study design
This study is a clinical trial of 81 functional constipa-
ted children, referred to the Pediatric Gastroenterology
Department of Amirkola Children’s Hospital (Babol,
Mazandaran, IRAN), from June to September 2011.
After obtaining informed consent from the parents, the
children were divided through a systematic randomization
into two parallel therapeutic groups: CFE and MO.
The study was approved by the Ethics Committee
of Shahed University and was registered in IRCT
(ID: IRCT201107026932N1).
The patients were treated for three weeks. The investi-
gators, the children and their parents were aware of the
study group assignment.
Inclusion criteria
Age between 4–13 years old and presence of FC were
the inclusion criteria.
Functional constipation was defined by a duration of
≥2 months of at least 2 or more of the following charac-
teristics: ≤ 2 defecation in the toilet per week, ≥ 1 episode
of fecal incontinence per week, history of retentive pos-
turing or excessive volitional stool retention, history of
painful or hard bowel movements, presence of a large
fecal mass in the rectum, history of large diameter stools
that may obstruct the toilet. These criteria are Paris Con-
sensus on Childhood Constipation Terminology criteria
[29] as Rome III criteria of functional constipation [30].
The children with inclusion criteria were visited by the
pediatric gastroenterologist to provide complete FC cri-
teria. If history and physical examination could not
prove FC, paraclinics like anorectal manometry, thyroid
function tests, anti-tTG, and other laboratory tests were
performed. If it was confirmed to be FC and the parents
were willing the children were entered to the study.
Exclusion criteria
Any symptom of organic constipation in the history, phys-
ical examination or paraclinics (such as hypothyroidism,
Hirschsprung disease, chronic intestinal pseudo-obstruction
and the presence of other chronic diseases that lead to
long-term use of drugs and long-term consumption of any
drug that can cause constipation.
Drop out criteria
Intolerance of taking drugs comes in the form of nausea,
vomiting, severe abdominal pain, allergic protests, incor-
rect use of medication and the patient's unwillingness to
continue treatment
Entering the study
All the children who were referred for treatment of FC
were eligible for the study.
If FC was confirmed, the detailed history was taken
and recorded in a sheet. In this sheet, the demographic
information were recorded. In addition, the average
of frequency defecation, retentive posturing, fecal incon-
tinence and large bowel movement per week were
questioned.
Also the parents of the children were trained to deter-
mine the average severity of pain and the average of
consistency of stools defecated in the previous days with-
out the use of any laxative. These scores were measured
on the pattern of Visual Analog Scale (VAS) [31-34].
Scores for the severity of pain during defecation were
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pain imaginable for parents), and also, scores for average
of consistency of stools defecated were in the range be-
tween 0 (soft and comfortable) and 100 (maximum
consistency imaginable for parents).
The parents learned to compare pain and consistency
of stool everyday during the study with these scores. If
the situation would have been better, the scores would
be less than these scores, and so on.
In physical examination, the presence of an abdominal
fecal mass and/or rectal mass and any anal lesion such
as fissure, hemorrhoid and fistula was examined.
The treatments started with demystification. If any
fecal mass was found, disimpaction was done with nor-
mal saline. Regular toilet sittings for 5 minutes after each
meal and diet changes were recommended to all the
children and then maintenance therapies in two groups
were started.
Safety profiles
During every visit and phone call, the parents were
questioned with respect to diarrhea, abdominal pain and
cramps, anal leakage, exacerbation of constipation, nau-
sea and vomiting, dermatologic complaints, weakness,
edema, palpitation or any other adverse effects.
Follow-up
Clinical efficacy and tolerance were assessed using
weekly sheets, parents completed every night. They were
given three sheets (included seven questions in seven
columns) to complete them daily for 3 weeks.
The parents were asked to complete the following: epi-
sodes of defecation, fecal incontinence, oily leakage and
retentive posturing per day. If the defection occurred at
least once a day, the average of severity of pain and
consistency of stool would be written compared with
what declared in the beginning of study.
In addition, the parents were asked to explain the
acceptance and tolerance of drugs on the bases of our
definition, from numbers 1 to 7: taking drug, with
willingness, score 1. Taking with no resistance, score 2,
and with objections, score 3. Taking with objection and
also allurement, score 4. Taking forcefully, score 5. Does
not easily take it by force, but tolerate it, score 6. Vomit-
ing, if anyway takes it, score 7.
These concepts and scores were exactly defined and
explained to the parents. In every phone call, they were
asked to repeat these definitions and talked about them
again to achieve their unique meaning. Once every 2–3 days
we called up the parents, and if it was necessary and pos-
sible spoke with the child. In these calls, they were asked
about filling out forms, therapeutic effects and any side
effects of the drugs. If there were any serious questions
or problems, we visited the child. In average, each child
in the course of study was visited three times and had six
phone calls.
At the end of 3 weeks of treatment, the children
were visited by the pediatrics gastroenterologist. The
filled out sheets were evaluated. If there was a serious
mistake in filling out the forms, after explaining it,
they were corrected by the parents.
Preparation of CFE
The dried fruits of cassia fistula was purchased from
local herbal drugs market in Tehran, Iran, and was iden-
tified by Herbarium of the Faculty of Pharmacy, Tehran
University of Medical Sciences, where the specimens of
cassia fistula were deposited under the voucher No.
PMP-618. The dried fruits were cut into pieces and after
isolating the seeds, they were soaked in sterile water.
Then with a filter, the aqueous solution of cassia fistula
was separated from the other parts. The solution was
concentrated with heat and under reduced pressure and
during concentration (according to TIM reference [11])
sugar and sweet almond oil was added in it, to produce
heterogeneous emulsion. Every 1 ml of this emulsion
contained 0.1 g of dried pulp of fruits of cassia fistula.
Dosage
The children received initially either 1 ml/kg/day MO
(manufactured by Hannan co., Brujen, Iran) or 0.1 g/kg
body weight daily of CFE.
In Physicians’ Desk Reference for Herbal Medicines
for cassia fistula, the daily dose of 4–8 gram of fruit
pulp is recommended [35]. In TIM references, using it
up to 20 gram per day is permitted [36].
To obtain an effective dose of CFE, it was used in a
step-by-step increasing manner in 3 adults and then 5
children from the dose of 0.05 g/kg (from dried pulp of
cassia fistula) in a pilot study. After this stage, it seemed
that the effective safe dose of emulsion was 0.1 g/kg. So
we started to prescribe it and adjust the dose every 3 days
by calling up the parents. The parents were provided
with guide. The results of the study lines regarding on
how to adjust the dosage of medication. In case of diar-
rhea, the dose was reduced 25%, and if it did not re-
spond well to medication, the dose was increased 25%,
all just for one time. MO was prescribed twice daily and
CFE in three-separated doses (after each meal).
Primary outcome
The results of the study were: [1] improvement in
defecation frequency per week [2] improvement in the
episodes of fecal incontinence per week [3] improvement
in the episodes of retentive posturing per week [4] im-
provement in the average of severity of pain of
defecation (by VAS) [5] improvement in the average of
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compliance.
Secondary outcome
Since the duration of therapy in this study was short, a
prolonged follow-up was not performed thus, judging
about long time recovery was not logical. However,
based on criteria Rome ІІІ, all the children enrolled this
study had at least two of the six criteria. To give a quali-
tative comparison between the two groups, the fre-
quency of positive criteria of Rome ІІІ in children was
calculated before medication, first, second and third
weeks of the study to compare with one another. During
3 weeks of medication, the patients that had less than 2
of the 6 criteria were called “improved”.
Statistical analyses
We hypothesized that CFE would be as effective or better
than MO in treating FC. There was not any previous
similar study. We estimated that 36 patients were
required in each group to be able to detect a difference
between the two groups, with 0.05 significance level at
0.80 power.
The data were entered in to SPSS (version 17), and
analyzed. Efficacy analyses (improved and not improved)
were performed with the intent-to-treat population,
defined as all children assigned randomly. Defecation
frequency, episodes of fecal incontinence, anal leakage of
oil, retentive posturing, severity of pain and consistency
of stool were calculated from the available follow-up
data. Comparisons were made between the initial data
and the follow-up data, between the first, second and
third weeks follow-up data, and within the groups. The
statistical analyses included the determination of means
and SDs, t test, χ
2 test, ANOVA repeated measures and
Fisher’s exact test, with significance accepted at the 5%
level. The results are expressed as mean ± SD or
percentage.
Result
From June to September 2011 among the 235 patients
visited for constipation, 81 patients with FC which
included 52(64.2%) boys and 29(35.8%) girls gave their
written informed consent and were then randomized to
receive the CFE or MO. All patients were followed-up
for 3 weeks. The last follow-up visit of the patients trea-
ted in both groups was in September 2011. Figure 1
shows a flow chart revealing how the patients in both
arms were selected for analysis.
The baseline characteristics of the patients in two
treatment groups were similar (Table 1). The age range
was between 49 to 132 months with the average of 67.7
(±21.9) months and mean of 60 months. Their mean
duration of constipation was 32.5(±24.3) months.
In this randomized, controlled, clinical trial in children
with constipation, CFE was more effective than MO for
the treatment of FC.
In all our criteria, both drugs were effective. In fecal
incontinence and retentive posturing, the results did not
have any significant differences between the two groups.
However, improvements in defecation frequency, sever-
ity of pain and consistency of stool were significantly
better in CFE group.
Excluded (n=154):
￿Age<4years (107 patients)
￿Using other drugs (15 patients)
￿Other organic diseases such as 
neurogenic problems (18 patients)
￿Hirschsprung disease (2 patients)
￿Poor tolerance and alertness of 
parents (12 patients)
Enrolment
81 patients 
randomized
Allocation 41 pts received the cassia fistula syrup 40 pts received the mineral oil
￿No compliance (n=3pts)
￿Lost of follow up (n=1 pts) n=37
n=37
n=37
n=38
n=37
n=34
￿No compliance (n=2pts)
￿Acceleration of constipation
(n=1 pts)
￿Acceleration of constipation
(n=1 pts)
￿Extra soiling (n=1 pts)
￿Intolerance of drug, because 
of fever and URI (n=1 pts)
Second week
medication
First week
medication
Third week
medication
Assessed for eligibility (n=235)
Figure 1 Flow chart summarizing the study process in the two treatment groups of the children with functional constipation.
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complication of MO, it did not occur in the CFE group
at all. Therefore, lack of this complication is one of the
most important advantages of CFE rather than MO.
In qualitative comparison between the two groups, im-
provement (exit from the criteria of FC) was significantly
better in CFE group.
The details of quantitative results are in Figures 2 and
3, and Table 2.
As a qualitative comparison between the two groups,
in the 1-week follow-up visit, 43% of the children in the
CFE and 39% in the MO group showed improvement .
These rates of the 2-week follow-up, were 62% in CFE
group and 41% in MO group. After a 3-week follow-up,
the improvement rate was significantly better in CFE
group, so that 84% in this group exited from the criteria
of functional constipation, but improvement in MO
group after 3 weeks was 50% (p = 0.002). The details are
in Table 3.
As we had known, anal leakage of oily material was
the most common complication of mineral oil [29]. It
occurred in 27 of 38 patients (71%) with the average of
10 ± 21 times per week in the first week, in 26 of 37
patients (70%) with the average of 10.8 ± 23 times per
week in the secondweek, and in 22 of 34 patients
(64.7%) with the average of 5.5 ± 7.3 times per week in
the third week. But this complication was not seen in
CFE group. The most common adverse effect in CFE
group was diarrhea. Twelve of the 37 patients (32%) in
this group by the dose of 1 mg/kg/day had it. All of
them recovered by decreasing 25% of the dose. Sputum-
like stool (2 times) was seen in one patient of this group.
Extra salivation in two patients and headache in one pa-
tient of MO group occurred, and recovered after the
study and withdraw the drug. Abdominal pain was seen
in 3 patients of each group.
In CFE group, no cases withdrew due to adverse
effects.
In MO group, four patients did not complete the total
duration of medication. A girl (66 months old (m/o))
withdrew after two weeks because of anal leakage of oily
material for more than 20 times per day. Two patients
withdrew using MO because of lack of response (A boy
of 54 m/o after 2 weeks and a girl of 65 m/o after
1 week).
In addition, a girl of 62 m/o withdrew taking MO after
2 weeks because of drug intolerance due to fever and
upper respiratory infection.
The average of compliance of drugs in two groups was
not significantly different (Table 2). Three patients
(59 m/o girl, 51 m/o girl, 71 m/o boy) in CFE group and
Table 1 Baseline data of the children with functional
constipation, in the two treatment groups of cassia
fistula emulsion and mineral oil
Variable CFE group
(n = 41)
MO group
(n = 40)
p value
Age, months, Mean(±SD) 69.4(±24.3) 65.9(±19.1) NS
Sex, Male, n (%) 29(70.7%) 23(57.5%) NS
Weight, Kg(±SD) 21.7 (±7.2) 20.7(±7.8) NS
Duration of constipation,
months, Mean(±SD)
34.2(±25.9) 30.8(±22.8) NS
Defecation≤2 per week, n (%) 32(78%) 30(75%) NS
Incontinence, n (%) 31(75.6%) 27(67.5%) NS
History of previous treatment, n (%) 32(78%) 28(70%) NS
Fecal impaction, n (%) 23(56.1%) 21(52.5%) NS
Retentive posturing, n (%) 32(78%) 29(72.5%) NS
NS: Not Significant.
A          B                                               C
Figure 2 A: Defecation frequency, B: Fecal incontinence and C: Retentive posturing (C) in the two treatment groups of cassia fistula
emulsion and mineral oil, in the children with functional constipation, before and after medication.
Mozaffarpur et al. DARU Journal of Pharmaceutical Sciences 2012, 20:83 Page 5 of 9
http://www.darujps.com/content/20/1/83two patients (71 m/o boy, 81 m/o girl) in MO group
refused to take them, because of the medicine taste.
Only one patient (52 m/o girl) in CFE group missed to
be followed-up. We mentioned her FC clinically. Never-
theless, she did not use the drug at all, and had gone to
another center, underwent rectal biopsy, ruled out
Hirschsprung disease and began to use poly ethylene
glycol (PEG).
Discussion
Cassia fistula has been used more than ten centuries in
TIM [9,10,37-39]. The most important phytochemical
constituents of cassia fistula are potent phenolic
antioxidants such as anthraquinones, flavonoids and
flavan-3-ol derivatives [11]. Anthraquinone is respon-
sible for its laxative effect and so it can be categorized as
stimulant laxative [5,27].
MO or liquid paraffin that was used in control group,
is the most commonly used lubricant laxative [5,28]. It is
composed of saturated hydrocarbons obtained from pet-
roleum. MO acts by coating and lubricating stools, redu-
cing colonic absorption of fecal water and facilitating the
evacuation of the stools. MO is not chemically active and
serious adverse effects are uncommon. Lipoid pneumo-
nia may occur rarely because of MO aspiration [28]. We
prefer to choose MO to use in control group because of
Table 2 Outcome data of the children with functional constipation, in two groups of cassia fistula emulsion and
mineral oil, before and after medication
Before medication First week Second week Third week
Defecation /w (±SD) Cassia fistula 1.7(±1.3)
NS 10.7(±6.4)
c 11(±6)
c 10.6(±5.7)
c
Mineral oil 2(±1.7) 5.8(±4.3) 5.8(±4.3) 6.1(±4.5)
Fecal Incontinence /w (±SD) Cassia fistula 19.2 (±21.7)
NS 4.9(±10.4)
NS 3.9(±10.1)
NS 3(±9.1)
NS
Mineral oil 16.6 (±18.7) 6.1(±11.5) 6.3(±11.8) 6.4(±11.1)
Retentive Posturing/w (±SD) Cassia fistula 17.7 (±19.9)
NS 6.8(±14.5)
NS 6(±12.5)
NS 4.1(±8.9)
NS
Mineral oil 15.3 (±17.7) 5.9(±9.6) 5.5(±9.9) 4(±8.8)
severity of pain (VAS) (±SD) Cassia fistula 60.9(±21.5)
NS 19.8(±17.8)
a 9.5(±11.7)
c 4.8(±8.5)
c
Mineral oil 58.1(±22.6) 31.5(±23.1) 24.8(±21.1) 20.1(±19.9)
consistency of stool (VAS) (±SD) Cassia fistula 71.9(±11.9)
NS 24.2(±21)
c 16.2(±16.9)
c 11.9(±16.8)
b
Mineral oil 70(±15) 42.1(±22.8) 32.3(±24.2) 25.4(±22)
Acceptance and Tolerance (±SD) Cassia fistula - 2.8(±1.7)
NS 2.5(±1.5)
NS 2.2(±1.5)
NS
Mineral oil - 2.7(±.5) 2.4(±1.4) 2.4(±1.3)
/w: per week, VAS: Visual Analog Scale, NS: Not Significant,
ap < 0.05 vs mineral oil,
bp < 0.01 vs mineral oil,
cp < 0.001 vs mineral oil.
A B
Figure 3 A: Severity of pain and B: consistency of stool, in the two treatment groups of cassia fistula emulsion and mineral oil, in the
children with functional constipation, by the score of Visual Analog Scale.
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FC with a good safety profile and fewer side effects and
our health center’s long time experience on it.
Although constipation is a common chronic problem,
there are very few studies with children comparing using
different laxatives [40]. Consequently, there is a lack of
large well designed placebo – controlled trial in this field
[41].
In a comparative study by Urganci N et al., MO was
more effective than lactulose in treatment of 40 children
with constipation. It responded more rapidly and
showed fewer side effects [42]. In another study; Hasan
Karimi et al., compared MO with PEG in 103 functional
constipated children. The results were better in PEG
group, but no significance between the two groups [43].
Martinez-Costa C et al., used MO accompanied with
senna in 62 children. Satisfactory results were achieved
1 month later in 32% of the children, 3–6 months later
in 71%, and 6–12 months later in 85% [44]. Clinical trial
in FC, with herbal source laxative is rare. Senna in this
study was effective in 85% of children after 6–12 months
accompanied with MO. but in our study, this rate of ef-
fectiveness was achieved after 3 weeks of treatment, only
with CFE. Senna (cassia angustifolia) and cassia fistula
are both anthranoid laxatives [27] but the prolonged use
of senna leads to more prevalent and important compli-
cations than cassia fistula [35].
Although PEG is now one of the choices of drugs,
studies are not absolute. Attar A et al., in 1999 com-
pared a low dose PEG 3350 with lactulose. Their results
were not conclusive but they said that low dose PEG
3350 was more effective than lactulose and better toler-
ated [45]. In 2002, Vera Loening et al., compared PEG
with milk of magnesium (MOM) for 49 children. In this
study, in the 12-month visit, 61% of children on PEG
and 67% on MOM were doing well [46]. In another
study, they compared PEG and MOM in 79 children for
12 months. The difference of efficacy was not significant
between the two groups, but the acceptance of PEG was
better than MOM [40].In another study PEG was found
to be as effective as lactulose [47]. In 2 randomized
trials, PEG with electrolytes was shown to be more ef-
fective than lactulose for 91 children over 8 weeks of
therapy [48] and for 51 children over a 3-month period
[49]. In another study PEG was used for 75 functional
constipated children. Constipation was relieved in 85%
with short-term (2 months) and in 91% with long-term
(11 months) PEG therapy [3].
Although there is not any unique definition and cri-
teria for FC, we used criteria of Rome III as inclusion
criteria and for measuring qualitative outcome of the
results. Our quantitative outcome measures were well
defined by the use of these criteria.
For entering in the study, three steps of explanation,
disimpaction and maintenance therapy were performed.
Also for disimpactions, we had different choices, but we
used enema with normal saline that has been effective in
relieving fecal impaction [50].
Close follow-up was one of strength of this study. We
called up all the parents every 3 days and talked with
them about their children and in case of any changes in
their bowel movement habit and other medical pro-
blems. Therefore, all of them trust us and because of this
good follow-up, we missed only one patient during the
study.
In this study, like more other studies in this subject, it
was not possible to perform a blind study because these
two drugs have different colors, tastes and smell and
were administered to children in different ways. Also,
because it was the first time cassia fistula was used in
children, we should be very careful about it and its prob-
able complications.
Another issue in this study was the age of the children
entered into the study. Because we were not confident of
the safety of drugs, we preferred children older than
4 years for our study. This problem led to a large number
of children referred not able to complete the inclusion
criteria.
Table 3 Comparison the effect of treatment in the children with functional constipation, in two groups of cassia fistula
emulsion and mineral oil, before and after medication
Number of present
criteria/the total criteria
of Rome III
BEFORE MEDICATION FIRST WEEK SECOND WEEK THIRD WEEK
Cassia
fistula
Mineral
oil
Cassia
fistula
Mineral
oil
Cassia
fistula
Mineral
oil
Cassia
fistula
Mineral
oil
(n=41) (n=40) (n=37) (n=38) (n=37) (n=37) (n=37) (n=34)
Inside the criteria
of Rome ІІІ
6 / 6 4 2 000000
5 / 6 1 1 9 041213
(Not improved) 4/6 15 17 4 4 1 4 1 2
3 / 6 9 6 471805
2/6 2 6 13 8 11 8 4 7
Out of criteria 1/6 - - 8 8 10 9 12 8
(Improved) 0/6 - - 8 7 13 6 19 9
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children entered into the study to be visited by pediatri-
cians, before. Most patients have already received medi-
cation, but mostly without good result. Some of these
patients were refractory to the treatment.
Probably, if the drug would have been used in younger
children and as first choice, we could have had better
responses and a lower dose of drugs might be needed.
Our baseline characteristics of patients in the two
groups were well matched. They were similar to other
literatures [40] except in fecal incontinence. In other
studies, its frequency differs between 8 to 15.6 episodes
per week [40,43,46,48,51], but in our study, it was higher
to some extent. It might be because fecal impaction is
one of the complications of prolonged constipation, and
as our health center is a tertiary and referral one, most
of the children entered in to the study had long time his-
tory of constipation and taking laxative drugs before.
A short follow-up period is a limitation of our study.
One reason for this matter was that, in this study we
wanted to demonstrate the effectiveness of CFE as a new
drug in the treatment of FC but the Ethics Committee
did not permit us to deprive the children from the usual
treatment, longer than 3 weeks. This short period of
follow-up is current in the first studies in other drugs in
this field, for example, this period for PEG was 2 to
4 weeks [45,47]. It was 4 weeks for probiotics [52] and
2 weeks for cellulose [53]. Comparing the effectiveness
and possible complications of its long-term use should
be investigated in the future studies.
In our study, since the drug dose in patients with CFE
was 0.1 g/kg/day, most of our patients had previous medi-
cations and might have drug resistance to some extent, so
we recommend to the patients to start 0.08 to 0.1 g/ kg/
day, based on dried pulp of fruits of cassia fistula.
There was no significant difference between the com-
pliance of the two drugs in three weeks. The acceptance
of MO in three weeks did not differ significantly, but the
acceptance of CFE in the first and second week was less,
but in the third week, it was better. It might be because
the children found it effective and tolerated its taste.
Conclusion
We offer CFE (cassia fistula emulsion) to be used for
treatment of FC (pediatric functional constipation), al-
though further researches about its safety should be
done. Comparison with other laxatives such as PEG and
senna for longer time is recommended.
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